Pivotal phase III COMPOSE trial will compare Lu-177-edotreotide with best standard of care for welldifferentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors
JOURNAL OF CLINICAL ONCOLOGY（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要